Abstract: Objective To investigate the maximum-tolerated dose（MTD） and observe the side effects of lobaplatin（LBP） combined with adriamycin（ADM） and ifosfamide （IFO） for neoadjuvant chemotherapy in osteosarcoma.
MethodsThe doses of ADM and IFO were fixed（ADM 60mg／m²，IFO 12g／m²），and three dose levels of LBP were setted， namely 45mg／m²， 50mg／m²， 55mg／m². The dose of LBP would increase gradually until doselimiting toxicity（DLT） or 55mg／m². Results Six cases were enrolled， and 2 DLT cases were observed when the test to the first dose group. So the MTD was LBP 45mg／m2， ADM 60mg／m²， IFO 12g／m². The main toxicities were reversible bone marrow suppression. The incidence rate of thrombocytopenia was 66.6％ （4／6） and grade 3 was 33.3％ （2／6）. The incidence rate of leukocytopenia was 83.3％ （5／6） and no grade 3-4 toxicity was observed 0 （0／6）. The incidence of neutropenia was 83.3％ （5／6） and grade 4 was 33.3％ （2／6）. All patients were recovered by symptomatic treatment. Conclusion The MTD of LBP combined with ADM and IFO as neoadjuvant chemotherapy in treating osteosarcoma is LBP 45mg／m2， ADM 60mg／m²， IFO 12g／m². The therapy is well tolerated and recommended as a basis for further clinical studies.